AirNet Technology raises $180 million in digital assets offering
In recent filings with the Securities and Exchange Commission, Venkatachaliah Girish, Chief Technology Officer of agilon health , inc. (NYSE:AGL), disclosed a transaction involving the withholding of shares to cover tax obligations. The company, currently trading at $4.32 and showing strong momentum with a 127% year-to-date return according to InvestingPro, maintains a healthy balance sheet with more cash than debt. On March 14, 2025, Girish had 3,311 shares of common stock withheld by the company at a price of $4.05 per share, amounting to a total value of $13,409. This transaction was related to the net settlement of performance-based restricted stock units (PSUs) that vested on the same day.
The PSUs were granted on April 14, 2022, and their vesting was contingent upon agilon health’s performance metrics, specifically Revenue and Adjusted EBITDA goals over a three-year period ending December 31, 2024. The company achieved 87% of its targeted goals, leading to the vesting of these units. Following this transaction, Girish holds 155,120 shares directly.
In other recent news, Agilon Health reported its fourth-quarter 2024 earnings, showing a 44% year-over-year revenue increase to $1.52 billion, surpassing forecasts. Despite the revenue growth, the company posted an earnings per share (EPS) of -$0.26, missing the anticipated -$0.22. Truist Securities maintained a Hold rating on Agilon Health, adjusting its revenue forecasts for fiscal years 2025 and 2026 to $5.9 billion and $6.2 billion, respectively, down from previous estimates. Additionally, Truist expects Agilon Health’s adjusted EBITDA loss to be $86 million in 2025 and $49 million in 2026.
Benchmark analysts raised their price target for Agilon Health to $4.00, maintaining a Buy rating, citing a quarter that aligned with expectations and a conservative forecast for fiscal year 2025. The company plans to exit two unprofitable physician partnerships and anticipates a 4% decrease in Medicare Advantage membership while gaining approximately 20,000 new members through new partnerships. Stifel analysts also increased their price target to $3.00, keeping a Hold rating, and highlighted Agilon Health’s strategic shift towards profitability over growth for 2025.
These recent developments reflect Agilon Health’s ongoing efforts to navigate a challenging market environment while focusing on strategic initiatives to improve financial performance and manage costs effectively.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.